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Abstract
Background: Cystic fibrosis is rare in Tunisia.Its diagnosis requires experienced specialists. Its prognosis is poor in developing 
countries.
Objectives: To study the epidemiologic, clinical, genetic features and the therapeutic challenges of  cystic fibrosis in Tunisian 
children.
Methods: Covering a period of  21 years, this retrospective study included all patients with a definite diagnosis of  cystic fibrosis 
from the Pediatrics Department B of  The Children’s Hospital of  Tunis.
Results:  Data from 32 children (14 boys and 18 girls) were collected. The diagnosis was made during the first year of  life in 28 
cases. Meconium ileus was found in 5 cases, respiratory manifestations in 22 cases, chronic diarrhea in 19 cases, faltering growth 
in 17 cases and a pseudo Barter syndrome in 2 cases. The sweat chloride test was positive in all cases. The most frequent mutation 
was F508del (56% of  cases).  Respiratory complications marked the outcome. Among our 32 patients, 15 patients (50%) died at 
an average age of  5 years and 3 months, mainly due to respiratory failure. The mean age of  the surviving patients was 5 years.
Conclusion:  Cystic fibrosis prognosis is poor in our series compared to developed countries due to the longer diagnostic delay 
and the limited therapeutic options.
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Introduction
Cystic fibrosis (CF) is a genetic disease; most definitely 
serious, transmitted in the autosomal recessive mode. It 
appears to be rare disease in the African countries. Its 
incidence is higher reaching 1 case / 4500 births in Eu-
rope and the USA1. Much better known in Europe and 
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America, cystic fibrosis occurs in individuals with inher-
ited two mutated CFTR genes located on the long arm 
of  chromosome 7 and playing a fundamental role in the 
regulation of  the epithelial chlorine channels. More than 
2000 mutations of  this gene have been listed, giving dif-
ferent phenotypic tables, the F508del mutation being the 
most frequent.
Chronic and progressive, cystic fibrosis manifests very 
early in childhood, sometimes from birth. Clinical man-
ifestations are diverse; in its classical form, the disease 
is dominated by exocrine pancreatic insufficiency and 
chronic lung infection. The prognosis and the mortali-
ty are tightly affected by the respiratory disease1,2,3. The 
mortality rate reported in the American registry was 1.8% 
per year while this rate was between 30 and 50% in devel-
oping countries2,3.
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In Tunisia, cystic fibrosis was long considered a relatively 
rare condition. With the development of  diagnostic facil-
ities, several cases of  cystic fibrosis have been diagnosed 
in recent years posing real problems of  care for these 
children.
Thus, the increase in the number of  children suffering 
from cystic fibrosis, the severity of  this disease and the 
improvement in life expectancy have prompted us to car-
ry out this work in order to:
-Study the epidemiological and clinical characteristics of  
cystic fibrosis.
-Report the mutations most frequently reported in our 
series.
-Study the treatment modalities and therapeutic difficul-
ties encountered.





This retrospective study was carried out in child pulm-
onology referral unit (Children’s Department B in Be-
chir Hamza Children’s Hospital of  Tunis) from 1996 to 
2016. We collected all patients with a definitive diagnosis 
of  cystic fibrosis based upon positive sweat tests (Sweat 
chlorine greater than 60 meq / l) and the presence of  a 
mutation in the homozygous state or two heterozygous 
mutations on the gene encoding the CFTR protein.
Several techniques were performed for genotype diag-
nosis: DNA extraction was from peripheral blood. Poly-
merase chain reaction (PCR) and polyacylamide gel elec-
trophoresis, and reverse dot blot procedures were used to 
detect known point mutations. Denaturant gradient gel 
electrophoresis (DGGE) were used in a next step search-
ing for the unknown point mutations that are later iden-
tified by automated sequencing on ABIprism 310. This 
strategy allowed us to detect 17 different mutations locat-
ed on the different exons of  the CFTR gene.
Nucleotide numbers are derived from cDNA CFTRse-
quences (GenBank accession no. NM_000492). Muta-




Data was collected from patients’ medical records. For 
each patient, we noted the age at first symptoms and at-
diagnosis and the circumstances of  the CF discovery.We 
registered the existence of  a family history of  CF.
We analysed the clinical data at diagnosis and during the-
monitoring as well as the results of  the different investi-
gations made. The clinical data specified the presence of  
recurrent or persistent upper and lower respiratorysymp-
toms. The radiological exploration included a chestx-ray, 
chest CT scan, and echocardiography. The sputum cul-
ture was carried out at diagnosis, during an acute respi-
ratory exacerbation and/or during the monitoring. The 
lung function tests were performed by plethysmography.
They were based on the measurement ofthe specific air-
way resistance for the children aged more than four and 
on spirometry for those aged more thanseven. The  ste-
atorrhea was assessed in the biochemical department. De-
termination of  chloride ions in sweat was carried out in 
the biochemistry laboratory of  the Children's Hospital of  
Tunis, by iontophoresis with pilocarpine. Molecular bi-
ology data were analyzed; five classes of  mutations were 
defined based on their repercussions on synthesis, intra-
cellular progression and protein function. All the analyzes 
in molecular biology were carried out in the biochemistry 
laboratory of  the Hospital of  Béchir Hamza children of  
Tunis.The management of  the disease was also analyzed. 
The minimal required duration of  thefollow-up was two 
years.
Statistical analysis
This study wascross-sectional and descriptive. The data 
were entered using Excel software as qualitative and 
quantitative values. The variables were expressed as per-
centagesand compared using the Chi square test. The 
Chi-square test associations between mortality rate and 
diagnostic delay and age at diagnosis were appropriate. 
The significance level of  “p” was 0.05.
Results
The incidence of  cystic fibrosis in the Pediatric depart-
ment B of  the Children's Hospital Béchir Hamza de Tu-
nis was estimated at 1.5 new cases / year.Its prevalence 
was 0.4 per 1000 hospitalizations. The consanguinity rate 
was estimated at 63%. Twelve patients (40%) had a family 
history of  infant death in a context suggestive of  cystic 
fibrosis. Eleven patients (34.3%) had a family history of  
cystic fibrosis. 
The number of  new cases varied according to the year 
with extremes ranging from 1 case to 7 new cases / year. 
In our series, the number of  boys was 14 or 43.7% of  
the cases. The number of  girls was 18.  The sex ratio was 
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estimated at 0.77. In our series the regions most affected 
by cystic fibrosis were the north and the south of  the 
country.
Twenty-two patients (68.7%) were under the age of  6 
months at the time of  diagnosis.The diagnosis of  cystic 
fibrosis was confirmed in 28 patients (87.5%) before the 
age of  1 year. The mean age at diagnosis was 8.55 months 
± 14.42 [1 month-60 months]. Clinically, in the neonatal 
period, six had delayed emission of  meconium, defined 
by the absence of  meconium emissions beyond 48 hours 
of  life. Five patients (17%) had a neonatal occlusion due 
to meconium ileus. One case was associated with small 
bowel atresia.
Beyond the neonatal period, the revealing symptoms were 
recurrent bronchopneumonia in 21 cases (70%), chronic 
diarrhea in 19 cases (59.3%), and faltering growth in 17 
cases (53%).
Twenty-one patients had chronic respiratory signs (70%). 
The mean age of  onset of  respiratory symptoms was es-
timated at 4.3 months ± 7.6 [1 month-36 months].This 
symptomatology was present before the age of  3 months 
in 11 cases, between the age of  3 months and 12 months 
in eight cases and after the age of  1 year in one case. Ane-
mia was found in almost half  of  patients (53% of  cases). 
Six patients (18.7%) had cholestasis. They were less than 
3 months old. A pseudo-Bartter syndrome was observed 
in only two cases. Eight patients (25%) had hypoprotein-
emia with an estimated mean value of  47.87 g / l± 7.37 
[36-57 g / l]. 
The association edema-anemia-hypoproteinemia was 
found in two cases (6.2%). Exocrine pancreatic insuffi-
ciency was confirmed in 30 (93.7%) of  32 patients who 
had a dosage of  steatorrhea. A cytobacteriological initial 
examination of  sputum was practiced in all cases  and 
isolated at least one organism in 22 cases (68.7%). Twen-
ty-two patients presented a primary infection with Pseu-
domonas aeruginosa (68.7%)at a mean age of  41.5 months in 
our patients. The other types of  organisms isolated were: 
Staphylococcus aureus in 5 cases (15.6%), Haemophilus influ-
enzae in 5 cases (15.6%) and Klebsielle Pneumonia in three 
cases (9.4%). The cytobacteriological initial examination 
of  sputum was negative in ten cases (31.2%). The diag-
nosis of  cystic fibrosis was confirmed by carrying out two 
sweat tests in most cases, coupled to molecular biology. 
The sweat test was practiced in all cases. It was performed 
only once in eight cases, twice in 21 cases and three time 
in two cases. In the first test, all the results were posi-
tive. The average amount of  chloride salt rate in sweat 
was estimated at 99.35 mmol / L ± 24.38 [60-161mmol 
/ L].During the second test, it was estimated at 104.37 
mmol / L ± 21.4 [72-135]. For the molecular biology 
diagnosis, we extracted the DNA of  the totality of  pa-
tients. The technic used was the PCR method practiced in 
the biochemistry laboratory of  the Hospital of  Children 
Béchir Hamza of  Tunis. The results of  the mutations of  
30 patients are available. The F508del mutation was the 
most frequent (56% of  the alleles). It was homozygous 
in 15 cases (46.8%) and heterozygous in 4 cases (12.5%).
Molecular biology in parents and siblings was done in 4 
cases, they were all heterozygotes for F508 del mutation. 
A neonatal screening from an index case revealed the dis-
ease early in a patient. 
The E1104X mutation occupies the secondposition  in 
our series after F508del (7% of  the mutated alleles) fol-
lowed by the G542X mutation and 711 + 1G -> T (5% 
each) then the G85E mutation (3%) and the W1282X 
mutation(3%).
From a therapeutic point of  view, the management of  
meconium ileus was surgical in all cases. A curative an-
tibiotherapy, was administered  to  manage bronchopul-
monary exacerbation. Seventeen patients (53%) were 
considered chronic colonized by Pseudomonas aeruginosa. 
They received systematic intravenous antibiotic therapy. 
Respiratory physiotherapy, prescribed in all cases, was 
done regularly.
Fourteen patients underwent aerosol therapy (43.7%). 
The molecules used were the inhaled Colimycin® pre-
scribed in the long course in the interval of  the cures in-
travenous in patients with chronic colonization by pseudo-
monas aeruginosa. Inhaled corticosteroids were prescribed 
in 4 cases with clinical signs of  bronchial hyperreactivity.
Eight patients (25%) required long-term oxygen thera-
py because of  a chronic respiratory failure. It was only 
nocturnal in five cases and nocturnal and diurnal in three 
cases. The mean age of  long-term oxygen therapy use 
in our series was 73.13 months ±40.94 [11-136 months]. 
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Non-invasive ventilation was necessary in one case and 
this was at the age of  14 years.No patient had a pulmo-
nary transplantation.
Vitamin therapy was instituted in all patients with daily in-
take of  sterogyl, Ephynal * and intra-muscular vitamin K 
during hospitalizations. Eighteen patients (56.2%) were 
under poly-vitaminated syrups (Hydrosol polyvitaminin 
drops *, Alvityl *, Calvitalis *). A high dose of  vitamin 
intake (according to guidelines)was given to five patients 
with low vitamin serum levels. All patients were treated by 
pancreatic extracts. The mean dose was estimated to be 
6018.2 IU lipase / kg ± 2200.56 [2570-10714 PubMed U 
/ kg].Nutritional support was provided by discontinuous 
gavage for three patients (9.4%). No patient was given 
continuous flow enteral nutrition or parenteral nutrition.
In addition, 7 patients with anicteric cholestasis (21.9%) 
were treated by ursodeoxycholic acid.
NaCl oral supplementation was prescribed in 5 infants. 
This supplementation was increased during periods of  
heat.
The mean periodof  follow-up of  our patients was 61.28 
months ± 65.7 [0-20 years]. The respiratory evolution 
was marked by the occurrence of  several episodes of  
acute exacerbations. On the respiratory side, the primary 
infection with pseudomonas aeruginosa was detected in 22 
cases at an average age of  41.5 months. Chronicity was 
observed in 17 cases (53%) at an average age of  5 years 
and 4 months. Seventeen patients were given periodic an-
tibiotic therapy every 3 to 4 months. The mean age of  
these patients was 5 years, our oldest surviving patient is 
about 23 years old.
Complications were observed in the course of  the respi-
ratory disease with episodes of  haemoptysis in five cases.
Changes in respiratory function were unfavorable with the 
onset of  chronic respiratory failure in eight cases (25%) 
requiring long-term oxygen therapy at home. Fifteen pa-
tients (46.9%) developed bronchiectasis diagnosed by 
thoracic CT scan. Seven patients had spirometry which 
showed obstructive irresversible syndrome with a mean 
forced expiratory volume of  68%.
Hepatic involvement was marked by cirrhosis in one 
case (3.1 %) with esophageal varices at endoscopy.  Of  
the 5 patients over 10 years of  age, two patients (6.2%) 
developed type cystic fibrosis-related  diabetes. For the 
digestive symptoms, the outcome was marked by the 
restoration of  a normal transit, after the placing under 
pancreatic extracts. Of  our 24 patients followed on an 
average duration of  5 years and 4 months [3 months-19 
years], 11 had flatering growth. This failure to thrive was 
severe in six cases, moderate in two cases and mild in 
three 
cases.
Among our 32 patients, 15 patients (50%) died at an aver-
age age of  5 years and 3 months ± 5 years (3 months-14 
years and 3 months). Six deaths (40%) occurred before 
age 1 year. The circumstances of  death were dominated 
by respiratory exacerbations with acute decompensation 
of  chronic respiratory insufficiency, observed in 10 cases.
 
Discussion
Cystic fibrosis is rare in African countries but severe with 
a long diagnostic delay since neonatal screening is not 
practiced.
The prevalence of  cystic fibrosis is increasing worldwide. 
In Tunisia, cystic fibrosis was long considered a relatively 
rare condition. With the development of  diagnostic facil-
ities, several cases of  cystic fibrosis have been diagnosed 
in recent years4. However, its incidence and prevalence 
are still unknown5.
The largest series published in Tunisia is by Messaoud et 
al.6, over 16 years of  study (1990-2005). It covered 390 
children from different regions of  Tunisia. This work was 
carried out from the results of  the sweat test as there was 
a centralization of  the realization of  this test.
In our monocentric series, we collected 32 cases of  Cystic 
fibrosis over a 21-year period (1996-2016). The hospital 
prevalence was estimated at 0.4 / 1000.
The rate of  consanguinity was high in the different Ara-
bic and Tunisian series7,8,9. In our series consanguinity was 
noted in 19 couples. This could be explained by the habits 
inherent in our socio-cultural context.
The mean age at diagnosis was 8.55 months in our series. 
A considerable delay in diagnosis is observed in compar-
ison with the series of  developed countries, especially af-
ter the introduction of  systematic screening in the neona-
tal period, instituted in 2002 in France.
The average age of  clinical diagnosis of  cystic fibrosis, 
according to US data from the National Cystic Fibrosis 
Patient Registry, is seven months before the age of  sys-
tematic neonatal screening10,11.
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In the different regions where a screening policy exists, 
the median age at diagnosis is four to six weeks12.
On the other hand, the average age of  our patients is 
earlier than that reported in the series of  Meherzi and 
Boukari.13,14.
 
Initial symptoms associate recurrent bronchitis with a 
productive, per year annual cough9. The mean age of  on-
set of  respiratory symptoms was estimated at 4.3 months 
± 7.6 [1 month-36 months] in our series.
The past decade has seen significant advances in under-
standing of  the pathogenesis and progression of  lung 
disease in cystic fibrosis. Pulmonary inflammation, infec-
tion and structural lung damage manifest very early in life 
and is prevalent among preschool children and infants, 
often in the absence of  symptoms or signs, affects the 
prognosis and the quality of  life of  patients17,18.
The severity of  the respiratory involvement is due also to 
the early burden of  the chronic infection by the Pseudomo-
nas aeruginosa. The mean age of  colonization of  Tunisian 
patients is earlier: 5 years and 1 month in the  Chaabouni 
M and al series5, 5 years and 4 months [1-14 years] in our 
series, and 15.6 months Khemiri M and al series16. More-
over, colonization rates are higher in Tunisian patients 
(53%in our series, 83% in the Chaabouni series5 and 31% 
in the Khemiri series16). These differences cannot be at-
tributed only to genetic factors, but also to environmental 
factors, namely the unfavorable conditions in the sanitary 
premises favoring transmission of  cross-infection19 and 
the controversy over management20.
The cytobacteriological examination of  sputum was 
performed in our series 4 times a year, even in the as-
ymptomatic patient and during exacerbations before any 
antibiotic therapy. Its implementation in the course of  a 
course of  antibiotic therapy is indicated in order to eval-
uate the effectiveness of  the treatment25.
 
The digestive manifestations, represented mainly by 
chronic diarrhea, were present in 14.6% of  the cases in 
the French register15. On the other hand, this rate was 
higher in the Khatami series and in the Tunisian series (50 
% in Hlioui series26 and 60% in ours). This is explained 
by the policy of  neonatal screening and the early start of  
opotherapy preventing any chronic diarrhea in France.
Exocrine pancreatic insufficiency  affects 50% to 89.9% 
of  patients with cystic fibrosis14,27,28.
More than half  of  the newborns suffer from an exocrine 
pancreatic insufficiency as of  the first assessment. This 
percentage increases towards the end of  the first year of  
life, reaching almost 85% according to the national cystic 
fibrosis registry29. 
In our series it involved 85% of  patients.
In infants, exocrine pancreatic insufficiency may be as-
sociated with edema-anemia-hypoproteinemia. The fre-
quency of  this clinico-biological triad during cystic fibro-
sis varies from 5% to 19.4% of  cases according to the 
authors14,30.
Chronic diarrhea and exocrine pancreatic insufficiency 
can be one of  the numerous causes of  malnutrition fre-
quently seen in cystic fibrosis31. Hypotrophy was present 
in 12.4% of  cases in the French register15 while it was 
revealing of  the diagnosis in 88% of  the cases in the kaht-
ami series16. In the Tunisian series; hypotrophy was part 
of  the initial clinical picture in 53% of  the cases of  our 
series.
Like the exocrine pancreatic insufficiency, endocrine pan-
creatic insufficiency can be seen in subsequent years to de-
cades, usually not before the age of  10 with a prevalence 
of  20% in adolescents. It is associated with worselung 
disease, malnutrition and mortality32.
According to the basis of  the mutations of  the cystic fi-
brosis, more than 2,000 mutations of  CFTR gene have 
been identified to date33. In 2005, the genetic study of  
cystic fibrosis in Tunisia identified 17 mutations localized 
on different exons of  the CFTR gene. The most frequent 
mutation was F508 del  (50.7%) followed by the muta-
tion E1104X (16.18%) and 3 other mutations commonly 
found in the Mediterranean countries (G542X, W1282X 
and N1303K)6. In our series, the F508 del mutation is also 
predominant (56% of  alleles), followed by the E1104X 
mutation in four cases, both resulting in the absence of  
CFTR protein function and then a severe phenotype6.
Mortality in our series remains high (15 patients among 
32) compared to countries where the disease is detected 
at birth34.  The mortality rate in the American registry was 
1.8%2. Nationally, the mean age of  death varies from a 
country to another (22 months in the series Khemiri et 
al16, 5 years and 3 months in ours and 7 years in the series 
of  Hlioui. S and al26. This progress can be attributed to a 
better knowledge of  the disease and better management 
at the level of  the pediatric hospitals generally and our de-
partment especially. Given the severity of  the disease and 
the therapeutic difficulties, genetic counseling and pre-
natal diagnosis were proposed to families4. The neonatal 
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screening from an index case revealed the disease early in 
a patient. In the series of  Hlioui S and al26 an antenatal 
diagnosis was made in 9 families, the fetus was homo-
zygous in 3 cases. The identification of  new mutations 
should facilitate antenatal diagnosis of  cystic fibrosis in 
Tunisia.
Conclusion
Cystic fibrosis  is the most common inherited disorder 
in Caucasian populations, with more than 2000 cystic 
fibrosistransmembrane conductance regulator (CFTR) 
mutations presently described. The distribution of  the 
mutations ranges widely between countries and/or ethnic 
groups. CF in Tunisian children is rare  and  severe with 
predominance of  first classes of  mutations.
Further multi-centric studies are needed to study the gen-
otype–phenotype correlations.
 In order to improve the prognosis of  this disease in our 
region, we propose a national action plan witch  aim to:
•         Ensure better training of  primary care physicians 
in the early diagnosis of  the disease
•         Strengthen collaboration between adult pediatri-
cians and pneumologists to ensure continuity of  quality 
care in adulthood and to allow for a gradual and better 
tolerated transition by the patient.
•          Systematically institute a consultation for genetic 
counseling for parents of  index cases.
•         Create a national register for the census of  chil-
dren with cystic fibrosis in order to have more precise 
epidemiological data, in order to define the health needs 
at national level and to locate us at the international level.
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